Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...
Bristol-Myers Squibb (BMY) stock gained as the comany exceeded Q3 2024 financial forecasts, with strong revenue growth and ...
With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...
Sales of blood cancer drug Revlimid, which is now facing generic competition, dropped 11% to $1.41 billion in the quarter, ...
Princeton, N.J.-based Bristol Myers BMY had net income of $1.2 billion, or 60 cents a share, in the quarter, down from $1.9 ...
Pharmaceutical giant Bristol Myers Squibb (BMY) raises its full-year earnings guidance after topping third quarter estimates, ...
The pharmaceutical company posted third-quarter adjusted earnings a share of $1.80 on revenue of $11.9 billion.
The Associated Press on MSN5d
A promising schizophrenia drug showed mixed results. What does that mean for patients?Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...
Insider Monkey on MSN1d
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy Right Now?We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood ...
PRINCETON, N.J. — PRINCETON, N.J. — Bristol Myers Squibb Co. (BMY) on Thursday reported third-quarter profit of $1.21 billion. On a per-share basis, the Princeton, New Jersey-based company said it had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback